Iran Thalassemia Society v. Office of Foreign Assets Control

CourtDistrict Court, D. Oregon
DecidedOctober 14, 2022
Docket3:22-cv-01195
StatusUnknown

This text of Iran Thalassemia Society v. Office of Foreign Assets Control (Iran Thalassemia Society v. Office of Foreign Assets Control) is published on Counsel Stack Legal Research, covering District Court, D. Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Iran Thalassemia Society v. Office of Foreign Assets Control, (D. Or. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF OREGON

IRAN THALASSEMIA SOCIETY, a No. 3:22-cv-1195-HZ nonprofit organization; EB HOME, a nonprofit organization; H.K., an individual; A.M., an OPINION & ORDER individual; S.N., an individual; M.M., an individual; FZ.H., an individual; F.E., an individual; and NO CHILD SHOULD SUFFER, a nonprofit organization,

Plaintiffs,

v.

OFFICE OF FOREIGN ASSETS CONTROL; JANET YELLEN, in her official capacity as Secretary of the Treasury; and ANDREA GACKI, in her official capacity as Director of the Office of Foreign Assets Control,

Defendants.

Thomas H. Nelson Thomas H. Nelson & Associates 20820 E. Glacier View Road Zigzag, OR 97049 Brandon Mayfield The Law Office of Brandon Mayfield 14631 SW Millikan Way Beaverton, OR 97003

Attorneys for Plaintiff

Brian M. Boynton Principal Deputy Assistant Attorney General Alexander K. Haas Director, Federal Programs Branch Diane Kelleher Assistant Director, Federal Programs Branch Stephen M. Elliott Stuart J. Robinson Senior Counsel United States Department of Justice Civil Division, Federal Programs Branch 1100 L St. NW Washington, D.C. 20005

Natalie K. Wight United States Attorney U.S. Attorney’s Office, District of Oregon 1000 SW Third Ave., Ste 600 Portland, OR 97204

Attorneys for Defendants

HERNÁNDEZ, District Judge: This case concerns some of the unfortunate side effects that can result from foreign policy decisions of the political branches of our nation’s government. Plaintiffs are an Iranian organization representing the interests of individuals in Iran suffering from thalassemia, a genetic blood disorder; an Iranian organization representing the interests of individuals in Iran suffering from epidermolysis bullosa (“EB”), a genetic skin disorder; six Iranian citizens suffering from EB; and an Oregon domestic nonprofit formed to support Iranian children impacted by the United States Government’s sanctions on Iran. Plaintiffs claim that Defendants’ imposition of “maximum pressure” sanctions on Iran has cut off the delivery of needed medication and medical supplies to children in Iran afflicted with thalassemia and EB, leading to increased suffering and, in some cases, death. Am. Compl. ¶¶ 2, 8, ECF 6. They seek a preliminary injunction enjoining Defendants from imposing sanctions on any entity that provides

humanitarian aid in the form of medical supplies and medications to Iran. The Court held oral argument on the Motion on September 23, 2022. While the Court is sympathetic to the plight of the impacted children, any solution is beyond the Court’s power to grant. The Court therefore denies Plaintiffs’ Motion for Preliminary Injunction [2]. BACKGROUND In 2018, then-President Donald Trump reimposed certain economic sanctions with respect to Iran. Pl. Mem. 1-2, ECF 2-1; Def. Opp. 1, ECF 7. These sanctions, which Plaintiffs refer to as “maximum pressure” sanctions, imposed new restrictions on Iranian banking entities. Pl. Mem. 2-3; Def. Opp. 5-6. Defendant Office of Foreign Assets Control (“OFAC”) administers the sanctions programs. Def. Opp. 2. Plaintiffs allege that these sanctions resulted in so-called

secondary sanctions on non-Iranian banks seeking to do business with Iran, which has made it virtually impossible for entities wishing to provide humanitarian aid to Iran to do so. Pl. Mem. 3. Defendants counter that the sanctions do not prohibit humanitarian aid and that OFAC has developed mechanisms to facilitate aid. Def. Opp. 18-22. According to Defendants, third parties are choosing not to do business in Iran. Id. at 22-23. Plaintiffs focus specifically on the impact of the secondary sanctions on Iranians with two medical conditions: thalassemia and epidermolysis bullosa (“EB”). According to Plaintiffs, “[t]halassemia major is a hereditary disease or disorder that causes anemia.” Pl. Mem. Ex. 1 (Medical Report of Dr. Nourbakhsh) at 1, ECF 2-2. Individuals diagnosed with thalassemia require blood transfusions, which in turn increase the iron load in the body. Id. They must regularly take iron-releasing drugs, or “iron chelators,” to counteract this effect. Id. Without these drugs, individuals with thalassemia may suffer from heart or liver failure resulting in death. Id. at 3. Plaintiffs allege that Desferal, the most effective iron-chelating drug, is no longer

available in Iran due to the sanctions. Pl. Mem. 3. Desferal is manufactured by Novartis, a Swiss- American pharmaceutical company. Id. Plaintiffs allege that Desfonac, the Iranian version of the drug, is less effective and causes several serious side effects. Am. Compl. ¶ 9. Plaintiffs allege that approximately 617 individuals with thalassemia in Iran have died since May 2018 because they were unable to access Desferal. Id. EB is a recessive genetic skin disorder that results in painful blisters forming on the skin. Pl. Mem. Ex. 3A (Parvizi Decl.) ¶ 6, ECF 2-3. Those diagnosed with EB require “daily wound care, bandaging, and pain management.” Id. Wounds may cover the majority of the individual’s body. Id. ¶ 10. Plaintiffs allege that the “maximum pressure” sanctions led a Swedish entity, Mölnlycke Health Care, to cease providing Mepilex, a specialized wound dressing, to Iranian

buyers. Pl. Mem. 3; Pl. Mem. Ex. 4, ECF 2-3 (letter to Plaintiff EB Home from Kristin Hedlund, Executive Vice President, stating that Mölnlycke Health Care is currently not doing business related to Iran due to the sanctions). Without the dressings, EB patients “are suffering excruciating pain as their wound dressings are changed.” Pl. Mem. 3. Plaintiffs represent that other wound dressings are not acceptable substitutes. Pl. Mem. Ex. 3A ¶¶ 11-12. Based on these harms, Plaintiffs filed a complaint against OFAC; its director, Andrea Gacki; and Treasury Secretary Janet Yellen. Plaintiffs allege two causes of action. Count I alleges violations of provisions of three federal statutes governing the President’s authority to impose economic sanctions: the International Emergency Economic Powers Act (“IEEPA”), specifically 50 U.S.C. § 1702(b)(2)1; the Trade Sanctions Reform and Export Enhancement Act (“TSREEA”), specifically 22 U.S.C. § 7202; and the Iran financial sector sanctions statute, specifically 22 U.S.C. § 8513a(d)(2). The provisions of these three statutes, Plaintiffs argue, prohibit the President from regulating or prohibiting humanitarian aid to Iran. Am. Compl. ¶¶ 45-

54. Count II alleges negligence under the Alien Tort Claim Act, also known as the Alien Tort Statute (“ATS”), based on a breach of Defendants’ duty toward Plaintiffs under the United Nations Convention on the Rights of the Child (“UNCRC”). Id. ¶¶ 55-63. Plaintiffs seek an injunction that “prohibit[s] OFAC from imposing sanctions on any entity, including but not limited to producers and their financial intermediaries, that engage[s] in the provision of humanitarian medical supplies and drugs to Iran.” Pl. Mem. 16. In the alternative, they seek “an injunction that would prohibit OFAC from imposing sanctions on any entity that provides or assists in providing medical treatments for thalassemia and epidermolysis bullosa.” Id. STANDARDS

A preliminary injunction is an “extraordinary remedy that may only be awarded upon a clear showing that the plaintiff is entitled to such relief.” Winter v. Nat. Res. Def. Council, Inc., 555 U.S. 7, 22 (2008).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Avero Belgium Insurance v. American Airlines, Inc.
423 F.3d 73 (Second Circuit, 2005)
Harmon v. Brucker
355 U.S. 579 (Supreme Court, 1958)
California v. Sierra Club
451 U.S. 287 (Supreme Court, 1981)
Asarco Inc. v. Kadish
490 U.S. 605 (Supreme Court, 1989)
Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
Sosa v. Alvarez-Machain
542 U.S. 692 (Supreme Court, 2004)
Nken v. Holder
556 U.S. 418 (Supreme Court, 2009)
Trudeau v. Federal Trade Commission
456 F.3d 178 (D.C. Circuit, 2006)
Samuel Lopez v. Janice Brewer
680 F.3d 1068 (Ninth Circuit, 2012)
Abagninin v. Amvac Chemical Corp.
545 F.3d 733 (Ninth Circuit, 2008)
Alexander v. Sandoval
532 U.S. 275 (Supreme Court, 2001)
Bernardo Mendia v. John Garcia
768 F.3d 1009 (Ninth Circuit, 2014)
Armstrong v. Exceptional Child Center, Inc.
575 U.S. 320 (Supreme Court, 2015)
Cindy Garcia v. Google, Inc.
786 F.3d 733 (Ninth Circuit, 2015)
Patrick Novak v. United States
795 F.3d 1012 (Ninth Circuit, 2015)
Navajo Nation v. Department of the Interior
876 F.3d 1144 (Ninth Circuit, 2017)
Lori Rodriguez v. City of San Jose
930 F.3d 1123 (Ninth Circuit, 2019)
San Diego County Gun Rights Committee v. Reno
98 F.3d 1121 (Ninth Circuit, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
Iran Thalassemia Society v. Office of Foreign Assets Control, Counsel Stack Legal Research, https://law.counselstack.com/opinion/iran-thalassemia-society-v-office-of-foreign-assets-control-ord-2022.